Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 μg and ethinylestradiol 15 μg (Minesse®)

Contraception

Volumn 73, Issue 1, 2006, Pages 30-33

  Barbosa, Ione C ^a   Filho, Carlos Isaia ^b   Faggion Jr , Dirceu ^c   Baracat, Edmund Chada ^d  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Centro de Medicina Reprodutiva Dr Carlos Isaia Filho   (Brazil)

^c DFJ Clínica Médica   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bleeding patterns; Contraceptives; Ethinylestradiol; Gestodene; Moos Menstrual Distress Questionnaire

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHINYLESTRADIOL PLUS GESTODENE; MINESSE; ORAL CONTRACEPTIVE AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; GYNECOLOGICAL EXAMINATION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NAUSEA AND VOMITING; NORMAL HUMAN; PHYSICAL EXAMINATION; PREGNANCY; QUESTIONNAIRE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; UTERINE BLEEDING PATTERN; VAGINITIS;

ADOLESCENT; ADULT; BLOOD PRESSURE; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; NORPREGNENES; PREGNANCY; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 29144508518     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2005.06.057     Document Type: Article

References (19)

1. L. Speroff, and A. De Cherney Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins Obstet Gynecol 81 1993 1034 1047
2. K. Fotherby, and A.D. Caldwell New progestogens in oral contraception Contraception 49 1994 1 32
3. M.I. Wilde, and J.A. Balfour Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations Drugs 50 1995 364 395
4. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg Eur J Contracept Reprod Health Care 4 Suppl. 2 1999 17 25
5. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg Eur J Contracep Reprod Health Care 4 Suppl. 2 1999 9 15
6. S.R. Johnson The epidemiology and social impact of premenstrual symptoms Clin Obstet Gynecol 30 2 1987 367 376
7. M. Steiner Premenstrual syndromes Annu Rev Med 48 1997 447 455
8. U.H. Winkler, H. Ferguson, and J.A. Mulders Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol Contraception 69 2004 469 476
9. T. Korver, E. Goorissen, and J. Guillebaud The combined oral contraceptive pill: what advice should we give when tablets are missed? Br Obstet Gynaecol 102 1995 601 607
10. H.P. Oosterbaan An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg on endometrial histological findings in healthy women Eur J Contracept Reprod Health Care 4 Suppl. 2 1999 3 8
11. P. Lammers, and M. Berg Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol Acta Obstet Gynecol Scand 70 1991 497 500
12. H. Sullivan, H. Fumiss, J. Spona, and M. Elstein Effect of a 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity Fertil Steril 72 1999 115 120
13. B. Dursterberg, H. Ellman, U. Muller, E. Rower, and B. Muhe A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene Gynecol Endocrinol 10 1996 33 39
14. F. Fruzzetti, A.R. Genazzani, C. Ricci, F. De Negri, C. Bersi, and F. Carmass A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control Contraception 63 2001 303 307
15. M.A. Lewis, W.O. Spitzer, L.A. Heinemann, K.D. MacRae, R. Bruppacher, and M. Throrogood Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women BMJ 312 1996 68 90
16. M.A. Lewis, W.O. Spitzer, L.A. Heinemann, K.D. MacRae, and R. Bruppacher Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism BMJ 315 1997 679 680
17. S. Rowlands Newer progestogens J Fam Plann Reprod Health Care 29 2003 13 16
18. C. Ross, G. Coleman, and C. Stojanovska Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology J Psychosom Obstet Gynaecol 24 2003 163 174
19. J. Borenstein, H.T. Yu, S. Wade, C.F. Chiou, and A. Rapkin Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life J Reprod Med 48 2003 79 85